ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population (38, 40)
A licensed clinician must prescribe it, and a licensed pharmacist must compound it for individual patient use
Our providers will work with you to choose the best option, considering insurance coverage and personal preferences, ensuring you receive optimal treatment
Hence, researchers have speculated that AOD 9604 may not be effective in increasing the size of muscle cells and contributing to muscle hypertrophy
Injecting them directly into the skin delivers them to where they can be most effective, resulting in improved health and vitality of the skin